



HAL
open science

Vaccination and COVID-19 Dynamics in Dialysis Patients

Khalil El Karoui, Maryvonne Hourmant, Carole Ayav, François Glowacki, Cécile Couchoud, Nathanaël Lapidus

► **To cite this version:**

Khalil El Karoui, Maryvonne Hourmant, Carole Ayav, François Glowacki, Cécile Couchoud, et al.. Vaccination and COVID-19 Dynamics in Dialysis Patients. *Clinical Journal of the American Society of Nephrology*, 2022, 17 (3), pp.395–402. 10.2215/CJN.10300721 . hal-03777518

HAL Id: hal-03777518

<https://hal.sorbonne-universite.fr/hal-03777518>

Submitted on 17 Oct 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Authors: El Karoui, Khalil; Hourmant, Maryvonne; Ayav, Carole; Glowacki, François; Couchoud, Cécile; Lapidus, Nathanael

Title: Vaccination and COVID-19 Dynamics in Dialysis Patients

Expedited Review: No

Running head: Vaccination and COVID-19 in Dialysis

Manuscript Type: Original Articles

Funders: FUNDREF :No data available.

Financial Disclosure: CUST_FINANCIAL_DISCLOSURE_-_ORIGINAL_ARTICLES_REVISÉ :No data available.

C. Couchoud reports serving on the Editorial Boards of BMC Nephrology, CJASN, and Nephrologie et Thérapeutique and other interests or relationships as a member of a not-for-profit association that aims to promote collaborations and research in Renal Epidemiology & Association des Néphrologues pour la Recherche en Épidémiologie (EPINEPHRO).

K. El Karoui reports employment with INSERM U955; research funding from Amgen, Otsuka, and Sanofi; and honoraria from Alexion, AstraZeneca, and Otsuka.

F. Glowacki reports research funding from Sanofi and honoraria from AstraZeneca.

M. Hourmant reports ownership interest in Sanofi.

The remaining authors have nothing to disclose.

Total number of words: 2933

Abstract: Background and objectives: Dialysis patients have a high mortality risk after COVID-19 and an altered immunological response to vaccines, but vaccine clinical effectiveness remains unknown in this population.

Design, setting, participants, and measurement: Using Bayesian multivariable spatiotemporal models, we estimated the association between vaccine exposure and SARS-CoV-2 severe infections (with hospital admission) in dialysis patients from simultaneous incidence in the general population. For dialysis patients, cases were reported within the French end-stage kidney disease REIN registry from March 11, 2020 to April 29, 2021, and vaccine exposure (first dose) was reported in weekly national surveys since January 2021. Cases in the general population were obtained from the national exhaustive inpatient surveillance system (SI-VIC database), and vaccination coverage (first dose) was obtained from the National surveillance system (VAC-SI database).

Results: During the 1st wave, incidence in dialysis patients was approximately proportional to the general population. However, we showed a lower relative incidence for dialysis patients during the 2nd wave (compared to that observed in non-dialysis patients), suggesting an effect of prevention measures. Moreover, from the beginning of the vaccination rollout, incidence in dialysis patients was reduced compared to predictions based on the 1st and 2nd waves. Adding vaccination coverages in dialysis and non-dialysis patients as predictors permitted to correctly fit the reported cases (3685 predicted cases, 95% CI: 3552, 3816 vs. 3620 reportedly). Incidence rate ratios (IRR) were 0.37 (95% CI: 0.18, 0.71) for vaccine exposure in dialysis patients, and 0.50 (95% CI: 0.40, 0.61) per 10% increase in vaccination

1
2
3 coverage in the same-age general population, meaning that vaccine exposure in dialysis patients and
4 general population was independently associated with lower hospitalization rate of dialysis patients.
5 Conclusion: Our findings suggest that vaccination may yield a protective effect against severe forms of
6 COVID-19 in dialysis patients, despite altered immunological vaccine responses.
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Vaccination and COVID-19 Dynamics in Dialysis Patients

Khalil EL KAROUI^{1,2}, Maryvonne HOURMANT³, Carole AYAV^{4,5}, François GLOWACKI^{4,5},
Cécile COUCHOUD^{4,5}, Nathanaël LAPIDUS^{6,7} ON BEHALF OF THE REIN REGISTRY

1. Assistance Publique Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, Service de Néphrologie et Transplantation, Centre de Référence Maladie Rare « Syndrome Néphrotique Idiopathique », Fédération Hospitalo-Universitaire « Innovative therapy for immune disorders », Créteil, France.
2. Univ Paris Est Créteil, INSERM U955, Institut Mondor de Recherche Biomédicale (IMRB), Equipe 21, Créteil, France
3. Nephrology Department, Nantes University Hospital, Nantes, France.
4. REIN Registry, Agence de la biomédecine, Saint-Denis La Plaine, France.
5. Université Lyon I, CNRS, UMR 5558, Laboratoire de Biométrie et Biologie Evolutive, Equipe Biostatistique Santé, Villeurbanne France
6. Assistance Publique Hôpitaux de Paris (AP-HP), Public Health Department, Saint-Antoine Hospital, Paris, France
7. Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique IPLESP, AP-HP, Sorbonne Université, Paris, France

Corresponding author: Dr Khalil EL KAROUI, MD, PhD. Department of Nephrology, Henri Mondor Hospital, APHP, Créteil, France. Tel +33149814415

khalil.el-karoui@aphp.fr

Abstract

Background and objectives: Dialysis patients have a high mortality risk after COVID-19 and an altered immunological response to vaccines, but vaccine clinical effectiveness remains unknown in this population.

Design, setting, participants, and measurement: Using Bayesian multivariable spatiotemporal models, we estimated the association between vaccine exposure and SARS-CoV-2 severe infections (with hospital admission) in dialysis patients from simultaneous incidence in the general population. For dialysis patients, cases were reported within the French end-stage kidney disease REIN registry from March 11, 2020 to April 29, 2021, and vaccine exposure (first dose) was reported in weekly national surveys since January 2021. Cases in the general population were obtained from the national exhaustive inpatient surveillance system (SI-VIC database), and vaccination coverage (first dose) was obtained from the National surveillance system (VAC-SI database).

Results: During the 1st wave, incidence in dialysis patients was approximately proportional to the general population. However, we showed a lower relative incidence for dialysis patients during the 2nd wave (compared to that observed in non-dialysis patients), suggesting an effect of prevention measures. Moreover, from the beginning of the vaccination rollout, incidence in dialysis patients was reduced compared to predictions based on the 1st and 2nd waves. Adding vaccination coverages in dialysis and non-dialysis patients as predictors permitted to correctly fit the reported cases (3685 predicted cases, 95% CI: 3552, 3816 vs. 3620 reportedly). Incidence rate ratios (IRR) were 0.37 (95% CI: 0.18, 0.71) for vaccine exposure in dialysis patients, and 0.50 (95% CI: 0.40, 0.61) per 10% increase in vaccination coverage in the same-age general population, meaning that vaccine exposure in dialysis patients and general population was independently associated with lower hospitalization rate of dialysis patients.

1
2
3 **Conclusion:** Our findings suggest that vaccination may yield a protective effect against severe
4
5 forms of COVID-19 in dialysis patients, despite altered immunological vaccine responses.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Patients with kidney failure requiring dialysis have a 20-25% risk of mortality after infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)¹⁻³. Besides, in-center hemodialysis is associated with a higher risk of contact with health care professionals or other high-risk patients, which may explain the elevated incidence of COVID-19 observed in dialysis patients in early 2020^{4,5}. To limit the transmission rate, infection prevention steps have been progressively taken in dialysis centers during the successive waves of the pandemics^{4,6}. Although these measures certainly had a major role in limiting disease transmission, the precise quantification of their effect is lacking.

The rapid development of vaccination against SARS-CoV-2 had a major role in controlling COVID-19 spread, since vaccines have shown a dramatic efficacy in preventing symptomatic forms of COVID-19, both in clinical trials and nationwide studies⁷. However, dialysis patients have been largely excluded from vaccine trials for safety reasons. Moreover, altered vaccine responses have been previously described in dialysis population, which justified to urgently characterize SARS-CoV-2 vaccine responses in dialysis patients. To date, this characterization remains mainly based on humoral responses post-mRNA vaccines: most studies showed a 80-95% rate of positive serology in dialysis patients after complete vaccination⁸, although this response appeared delayed and antibody levels slightly reduced when compared to the non-dialysis population⁹. These results led to prioritize vaccination in dialysis patients in France in early 2021, leading to a high vaccination coverage compared to the non-dialysis population. However, the evaluation of vaccine effectiveness against severe forms of COVID-19 in this population remains an unmet need.

In this work, we sought to characterize COVID-19 dynamics in dialysis patients at the population scale by using the general population incidence over time and space as a reflection of SARS-CoV-2 spread.

Materials and Methods

The French kidney failure REIN registry^{2,10} is intended to include all dialysis patients living in France. The national coordination center is based at the Agence de la Biomédecine, a public health agency that oversees the activity of organ and tissue procurement and transplantation. The REIN registry relies on a nationwide network of health professionals with exhaustive continuous registration of all dialysis patients. The participation rate of centers in all contributing regions is 100%. Thirty-two clinical research assistants regularly visit each dialysis center to check the completeness of patient and event registration and to ensure the quality of data. This study included all patients on dialysis on the French mainland and French overseas territories.

We analyzed aggregated weekly counts of severe SARS-CoV-2 infections (defined by infections followed by hospital admissions) in dialysis patients and in the French general population.

Cases in dialysis patients were reported within the REIN registry from March 11, 2020 to April 29, 2021^{2,10}. Vaccine exposure in dialysis patients (first dose) was reported in weekly surveys sent to all French nephrology centers since January 2021. To account for the possible source of missing data regarding reporting of severe cases (some patients may be recently diagnosed with COVID-19, or reported as having a mild disease as information on their hospitalization or death is not yet available until a retrospective reclassification can be made), we set a 6-week delay between the end of the period considered for the analysis (April 29, 2021) and data extraction (June 10, 2021).

Weekly incidences of severe infections in the general population were obtained from the national exhaustive inpatient surveillance system (SI-VIC database), assuming a 11-day time lapse from illness onset to hospitalization. The chosen 11-day lag applied to hospitalization

1
2
3 dates relies on previous estimates¹¹ and was already used in several modeling studies^{12–14}.
4
5 Weekly vaccination coverage (first dose) in the general population was obtained from the
6
7 National surveillance system (VAC-SI database)¹⁵.
8
9

10 We estimated the expected weekly incidence of severe infections in dialysis patients from
11
12 simultaneous cases reported for the same age class in the general population, using Bayesian
13
14 hierarchical Poisson regressions accounting for spatial autocorrelation, with the log number of
15
16 at-risk dialysis patients as an offset. Data was aggregated spatially at the department level
17
18 (administrative division of France; there are 96 metropolitan departments) and temporally at
19
20 the week level. Incidences and vaccination coverages were considered by 10-year age classes
21
22 (25-35, 35-45, 45-55, 55-65, 65-75, 75-85 and > 85 years). Notably, in order to estimate the
23
24 association of between vaccination in dialysis patients and their risk of severe infections at the
25
26 population scale, we used data on time- and space-dependent incidence in the general
27
28 population as a reflection of French incidence of SARS-CoV-2 infections (however, our study
29
30 was not designed to provide a direct comparison of individual infections in dialysis and non-
31
32 dialysis groups).
33
34
35
36
37
38

39 We built 3 statistical models. Model M₁ only used incident cases from the first epidemic wave
40
41 (up to June 30, 2020). Model M₂ used similar data up to the end of the second wave and
42
43 beginning of the vaccination campaign in dialysis patients (January 7, 2021), considering a
44
45 possible risk change between the two waves. Model M₃ used similar data up to April 29, 2021
46
47 with vaccine coverages in the general population and in dialysis patients as additional
48
49 predictors.
50
51
52

53 Among these models, M₁ (fitted from 1st wave data) was used to compare 2nd wave predictions
54
55 to reported cases and identify changes in factors associated with incidence in dialysis patients
56
57 from the beginning of the 2nd wave. M₂ (fitted from 1st and 2nd waves data) was used to compare
58
59 3rd wave predictions to reported cases and identify changes in factors associated with incidence
60

1
2
3 in dialysis patients from the beginning of the 3rd wave. M_3 (fitted from 1st to 3rd wave data) was
4 used to identify factors associated with incidence in dialysis patients globally.
5
6

7
8 Weekly vaccination coverage data were lagged by 3 and 5 weeks in the general population and
9 dialysis patients, respectively, to account for a possible effect of constituted immunity on
10 infection risk^{8,16–18}. We used a prolonged lag from vaccination in dialysis patients, given the
11 delayed vaccine response consistently observed in this population⁹ and conducted a sensitivity
12 analysis using 3-week lags in both populations. Only patients aged at least 25 years were
13 considered from all data sources. Statistical analyses are detailed in supplemental material. All
14 analyses were performed using R Statistical Software (Foundation for Statistical Computing, Vienna,
15 Austria) and the INLA package.
16
17
18
19
20
21
22
23
24
25

26
27 The institutional review board of the REIN registry gave ethical approval for this study protocol
28 (04/28/2021), in adherence to the declaration of Helsinki.
29
30

31 32 **Results**

33
34
35 Vaccination coverages in dialysis patients and the general population are shown in Figure 1A.
36 On April 8, 2021 (last date for which vaccinations were considered in this study), the
37 cumulative numbers of vaccine shots in mainland France were 10,255,204 and 3,406,601 for
38 doses 1 and 2, respectively. The global shares were 72.2% (9.8 M), 20.4% (2.7 M) and 7.4%
39 (1.0 M) for Pfizer/BioNTech, Astrazeneca and Moderna vaccines, respectively.¹⁵ A total of
40 53,635 at-risk dialysis patients were included in this analysis with an average follow-up time
41 of 11.7 (SD 2.1) months (627,529 person-months). Among them, 3620 SARS-CoV-2 severe
42 infections were reported (Figure 1B and Supplemental Table 2). Notably, throughout the period
43 of the study, we observed no significant change in the size of the dialysis population, which
44 varied from 45,035 to 46,750 (mean: 46,212). The size of the at-risk dialysis population
45 continuously changed since some patients entered the registry after the beginning of the study
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 while others were removed as they presented the endpoint (severe SARS-CoV-2 infection),
4 died or got a kidney transplant. In the meantime, 446,890 hospital admissions were reported in
5 the general population (Figure 1B and Supplemental Table 2). Cumulative incidences of severe
6 infections in dialysis patients were 2- to 28-fold higher in dialysis patients compared to non-
7 dialysis patients, according to epidemic wave (1st, 2nd or 3rd) and age strata (Supplemental Table
8 2). Model M_1 (using incident cases from the first epidemic wave) showed that during the first
9 wave, incidence in dialysis patients was approximately proportional to incidence in the general
10 population (Figure 1C, Table 1). Incidence rate ratios (IRR) describe how a factor modulates
11 the hospitalization risk of dialysis patients, assuming an otherwise proportionality with the
12 same-age general population. IRR were higher in young dialysis patients: compared to patients
13 aged 55-65 years, IRR were 4.04 (95% credible interval [CI]: 2.38, 6.51) and 0.87 (95% CI:
14 0.73, 1.04) in patients aged 25-35 and 75-85 years, respectively. This counterintuitive result
15 suggests that dialysis patients show a higher hospitalization risk than the general population
16 globally, and especially for younger dialysis patients, who have a relatively higher risk of
17 hospitalization than older dialysis patients, when compared to the same-age general population
18 (Table 2).

19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40 We next studied the observed cases during the second wave. Predictions from model M_1
41 overestimated incidence during the second wave, with 2092 predicted cases (95% CI: 1888,
42 2317) vs. 1447 reportedly (Figure 1C, Table 1). This suggests that prevention steps towards
43 dialysis patients during the 2nd wave were associated with a reduction in observed cases
44 compared to predicted cases based on first wave data.

45
46
47
48
49
50
51
52 We next developed a model M_2 based on data up to the end of the 2nd wave. M_2 estimated that
53 the risk in dialysis patients decreased between waves 1 and 2, with IRR = 0.70 (95% CI: 0.64,
54 0.76) (Table 2). While M_2 correctly estimated the reported dialysis cases up to the end of the
55 second wave (Figure 1C), predictions from this model overestimated the expected number of
56
57
58
59
60

1
2
3 cases from the beginning of the vaccination campaign (3rd wave): 1457 (95% CI: 1356, 1557)
4
5 vs. 940 reported (Figure 1C and Table 1). This suggests that other epidemiologic factors which
6
7 occurred during the 3rd wave have been associated with a reduction of observed cases, compared
8
9 to prediction modeled from the dynamics of the 1st and 2nd waves. We thus hypothesized that
10
11 vaccination policy might have been involved in this observation.
12
13

14
15 Using vaccination coverages as additional predictors in M₃ permitted to accurately estimate
16
17 overall incidence during the 3rd wave (3685 predicted cases, 95% CI: 3552, 3816 vs. 3620
18
19 reported) and to correctly approximate the weekly reported number of cases (Figure 1C, Table
20
21 1). Interestingly, using M₃, IRR were 0.37 (95% CI: 0.18, 0.71) for vaccine exposure in dialysis
22
23 patients, showing a ~3-fold reduction of hospitalization risk associated with vaccination.
24
25 Moreover, for dialysis patients, IRR were 0.50 (95% CI: 0.40, 0.61) per 10% increase in
26
27 vaccination coverage in the same-age general population, showing an inverse association
28
29 between incidence of severe infections in dialysis patients and vaccination of the general
30
31 population. This suggests that vaccine exposure in both dialysis patients and the general
32
33 population was independently associated with reduction of hospitalization rates in dialysis
34
35 patients, when compared to the same-age general population (Table 2). As for estimates from
36
37 previous models, IRR calculated from model M₃ in dialysis patients were higher in younger
38
39 patients: compared to dialysis patients aged 55-65 years, IRR were 2.92 (95% CI: 2.03, 4.09)
40
41 and 0.78 (95% CI: 0.70, 0.88) in dialysis patients aged 25-35 and 75-85 years, respectively.
42
43 This observation using model M₃ confirms that young dialysis patients had a higher risk than
44
45 older ones throughout the follow-up, when compared to the same age general population. We
46
47 then hypothesized that IRR associated with vaccine exposure may change according to age
48
49 strata and therefore estimated the interaction between age and vaccine exposure in dialysis
50
51 patients. We thus identified a lower IRR for vaccine exposure in younger patients.: compared
52
53 to patients aged 55-65 years, IRR were 0.04 (95% CI: 0.00, 0.46) and 1.74 (95% CI: 0.80, 3.86)
54
55
56
57
58
59
60

1
2
3 in dialysis patients aged 25-35 and 75-85 years, respectively. These results suggest a higher
4 impact of vaccination in reducing hospital admissions for younger dialysis patients, compared
5 to the same-age general population (Supplemental Table 3). Coefficients from these models are
6 reported in Table 2. Sensitivity analysis using 3-week lags in both populations disclosed similar
7 results (Supplemental Table 4).
8
9
10
11
12
13
14
15
16
17

18 **Discussion**

19
20
21 By modeling the dynamics of SARS-CoV-2 infections leading to hospital admissions among
22 dialysis patients in France as a proportion of cases reported in the general population, we
23 identified a relative reduction of cases in the 2nd wave, compared to a model based on the 1st
24 wave only. This result suggests that, accounting for the epidemiologic trends in the general
25 population, the hospitalization rate of dialysis patients in the 2nd wave was lower than expected
26 from data of the first wave. This observation may be explained by the progressive
27 implementation of prevention steps, earlier testing and better management of COVID-19 of
28 dialysis patients during the 2nd wave. Indeed, since the beginning of the epidemic, protective
29 strategies have been broadcasted by the French Society of Nephrology with weekly COVID-19
30 webinars. However, this effect could be also confounded by a trend to limit hospitalization of
31 dialysis patients with milder cases. Notably, although a similar downward trend in COVID-19-
32 related hospitalization and mortality since the first wave has been observed in the general
33 population in the US¹⁹, our results suggest an added reduction of adverse outcomes in dialysis
34 patients.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53

54 Moreover, our models also suggest a reduction of hospitalized cases starting in early 2021,
55 compared to a model based on the 1st and 2nd waves only. Therefore, we hypothesized that
56 vaccination exposure could have had a role in limiting hospital admissions in dialysis patients,
57
58
59
60

1
2
3 who were prioritized by French vaccine policies (Figure 1A). Taking into account vaccine
4 exposure in both the general population and dialysis patients using model M_3 , we (i) could
5 adequately predict the observed incidence during the 3rd wave, and (ii) found that the reduction
6 of cases was independently associated with vaccine exposure in both dialysis patients and the
7 same-age general population. These findings suggest that vaccination may have a protective
8 effect from the first dose in dialysis patients. Moreover, these patients may indirectly benefit
9 from vaccine policies at the population scale, probably thanks to a lessened exposure to the
10 virus from their encounters.

11
12 Interestingly, we quantified an IRR of 0.37 (95% CI: 0.18, 0.71) for vaccine exposure in dialysis
13 patients, meaning that vaccination was associated with a ~3-fold reduction in hospitalization
14 rate of dialysis patients, when accounting for the epidemiologic trends in the same-age general
15 population (Table 2). In a context of new variant spread with greater contagiousness, and
16 waning of antibody levels in vaccinated patients, the statistical method presented in this study
17 could allow quantifying the future persistence/decline of the protective effect of vaccination in
18 dialysis patients at the population scale.

19
20 Importantly, in our study, vaccine exposure data were dependent on weekly reports from
21 dialysis centers. Vaccine exposure could therefore be overestimated, since dialysis centers with
22 high vaccination rates might tend to better report their data. However, despite this potential
23 overestimation that would tend to undervalue the preventive effect of vaccination, we were able
24 to show a reduction of hospitalization rates associated with vaccine exposure in dialysis
25 patients. Consequently, vaccine exposure appears as a major factor associated with lower
26 hospitalization in dialysis patients in early 2021.

27
28 Using our different models, we detected that IRR were higher in younger dialysis patients,
29 compared to older dialysis patients. An explanation might be that dialysis is an additional risk
30 factor for all patients, but this higher risk is not as important in older patients (in whom age is

1
2
3 already a major risk factor) as in younger ones in whom severe infections are very rare in the
4
5 general population.¹ We thus hypothesized that vaccine impact on hospital admissions may also
6
7 vary according to age strata. Indeed, we identified an interaction between age and vaccine
8
9 exposure in dialysis patients leading to a lower IRR for vaccine exposure in younger dialysis
10
11 patients (Table 2). This result suggests a higher impact of vaccination in lowering hospital
12
13 admissions for younger dialysis patients, compared to older dialysis patients accounting for the
14
15 epidemiologic trends in the same-age general population (Supplemental Table 3). These data
16
17 could be related to a better vaccine response in young dialysis patients, as suggested in the
18
19 general population.²⁰ However, vaccine policies in the general population may also explain this
20
21 interaction. Indeed, in early 2021, vaccine policies for non-dialysis population targeted older
22
23 individuals (nursing homes patients from December 27, patients over 75 years since January
24
25 18, patients over 65 years since early March and patients over 50 years since late March).
26
27 Consequently, it is likely that a higher benefit of vaccine exposure in young dialysis patients
28
29 could be linked to the low vaccination coverage in the same-age general population (Figure
30
31 1A).
32
33
34
35
36

37
38 The strength of our analysis is the large number of patients followed in the dialysis population
39
40 since the beginning of the SARS-CoV-2 spread in France, thanks to the nationwide REIN
41
42 registry^{2,10}. However, in absence of individual data on vaccination, we were not able to evaluate
43
44 the individual risk of severe form of COVID-19 post-vaccination²¹. Moreover, our models did
45
46 not take into account the impact of previous SARS-CoV-2 asymptomatic or pauci-symptomatic
47
48 infection, given the difficulty to reliably detect such infections in dialysis patients.^{5,22} Besides,
49
50 whether this analysis could be extended to other populations with different prevention measures
51
52 (including types of vaccines and vaccination schemes) remains to be studied. Of note, our
53
54 analyses end before the strategy of third vaccine injection starts in France (in late April 2021).
55
56 Lastly, our data did not include important virological factors such as the spread of variant of
57
58
59
60

1
2
3 concern types in both populations.²³ However, no evidence to date suggests that SARS-CoV-2
4
5 variants may differently impact the relative susceptibility of dialysis patients compared to non-
6
7 dialysis ones.
8
9

10 In conclusion, this study identifies vaccination coverage in both dialysis patients and the general
11
12 population as independently associated with protection against severe infection in dialysis
13
14 patients. Though causal relationships cannot be demonstrated from such an observational study,
15
16 our findings suggest that both individual and herd vaccine-induced immunity may yield a
17
18 protective effect against severe forms of COVID-19 in dialysis patients.
19
20
21

22 23 **Disclosures**

24
25
26 C. Couchoud reports serving on the Editorial Boards of *BMC Nephrology*, *CJASN*, and
27
28 *Nephrologie et Thérapeutique* and other interests or relationships as a member of a not-for-
29
30 profit association that aims to promote collaborations and research in Renal Epidemiology
31
32 “L’Association des Néphrologues pour la Recherche en Epidémiologie (EPINEPHRO).”
33
34

35
36 K. El Karoui reports employment with INSERM U955; research funding from Amgen, Otsuka,
37
38 and Sanofi; and honoraria from Alexion, AstraZeneca, and Otsuka.
39
40

41 F. Glowacki reports research funding from Sanofi and honoraria from AstraZeneca.
42
43

44 M. Hourmant reports ownership interest in Sanofi.
45
46

47 The remaining authors have nothing to disclose.
48
49

50 51 **Funding**

52
53 The REIN registry is supported by the Agence de la Biomedicine, France.
54
55

56 57 **Acknowledgments**

1
2
3 We gratefully acknowledge all participants of the REIN registry — nephrologists and
4
5 research assistants alike. The centers participating in the registry are listed in the REIN annual
6
7 report: <http://www.agence-biomedecine.fr/Le-programme-REIN>.
8
9

10 **Author Contributions**

11
12
13
14 Khalil El Karoui: Conceptualization, Formal analysis, Supervision, Validation, Visualization,
15
16 Writing – original draft, Writing – review & editing
17

18
19 Maryvonne Hourmant: Investigation, Supervision, Writing – original draft
20

21
22 Carole Ayav: Data curation
23

24
25 François Glowacki: Data curation, Investigation
26

27
28 Cécile Couchoud: Data curation, Formal analysis, Investigation, Methodology, Resources,
29
30 Supervision, Validation, Visualization, Writing – review & editing
31

32
33 Nathanael Lapidus: Conceptualization, Data curation, Formal analysis, Investigation,
34
35 Methodology, Software, Supervision, Validation, Visualization, Writing – original draft,
36
37 Writing – review & editing
38
39

40 **Data Sharing Statement**

41
42
43
44 All data used in this study are available in this article.
45
46

47 **Supplemental Material**

48
49
50 Supplemental Table 1 : Description of the study populations
51

52
53 Supplemental Table 2 : Crude number of hospitalizations, total at-risk population, cumulative
54
55 incidence in dialysis and the general population and relative risk of hospitalization according
56
57 to age classes and epidemic waves
58
59
60

1
2
3 Supplemental Table 3 : Relative risks (95% credible intervals) of severe infection in dialysis
4 patients, predicted from model M3, between April 2 and April 8, 2021 in Paris
5
6
7

8 Supplemental Table 4 : Coefficients from the Poisson regression (exponentiated and reported
9 as incidence rate ratios with their 95% credible intervals): model M3 (3- and 5-week lags
10 between first dose and expected protection in the general population and in dialysis patients,
11 respectively) and additional model with 3-week lags for all.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. *Nature*. 2020;584(7821):430-436. doi:10.1038/s41586-020-2521-4
2. Couchoud C, Bayer F, Ayav C, et al. Low incidence of SARS-CoV-2, risk factors of mortality and the course of illness in the French national cohort of dialysis patients. *Kidney Int*. 2020;98(6):1519-1529. doi:10.1016/j.kint.2020.07.042
3. Jager KJ, Kramer A, Chesnaye NC, et al. Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe. *Kidney Int*. 2020;98(6):1540-1548. doi:10.1016/j.kint.2020.09.006
4. De Meester J, De Bacquer D, Naesens M, et al. Incidence, Characteristics, and Outcome of COVID-19 in Adults on Kidney Replacement Therapy: A Regionwide Registry Study. *J Am Soc Nephrol JASN*. 2021;32(2):385-396. doi:10.1681/ASN.2020060875
5. Clarke C, Predecki M, Dhutia A, et al. High Prevalence of Asymptomatic COVID-19 Infection in Hemodialysis Patients Detected Using Serologic Screening. *J Am Soc Nephrol JASN*. 2020;31(9):1969-1975. doi:10.1681/ASN.2020060827
6. Cherif A, Willetts JL, Usvyat L, Wang Y, Kotanko P. Comparative Analysis of SARS-CoV-2 Reproduction Rates in the Dialysis and General Populations. *J Am Soc Nephrol JASN*. Published online March 8, 2021:ASN.2020121691. doi:10.1681/ASN.2020121691
7. Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. *N Engl J Med*. Published online February 24, 2021. doi:10.1056/NEJMoa2101765
8. Ikizler TA, Coates PT, Rovin BH, Ronco P. Immune response to SARS-CoV-2 infection and vaccination in patients receiving kidney replacement therapy. *Kidney Int*. 2021;99(6):1275-1279. doi:10.1016/j.kint.2021.04.007
9. Van Praet J, Reynders M, De Bacquer D, et al. Predictors and Dynamics of the Humoral and Cellular Immune Response to SARS-CoV-2 mRNA Vaccines in Hemodialysis Patients: A Multicenter Observational Study. *J Am Soc Nephrol JASN*. Published online September 29, 2021:ASN.2021070908. doi:10.1681/ASN.2021070908
10. Couchoud C, Stengel B, Landais P, et al. The renal epidemiology and information network (REIN): a new registry for end-stage renal disease in France. *Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc*. 2006;21(2):411-418. doi:10.1093/ndt/gfi198
11. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet Lond Engl*. 2020;395(10229):1054-1062. doi:10.1016/S0140-6736(20)30566-3
12. Hozé N, Paireau J, Lapidus N, et al. Monitoring the proportion of the population infected by SARS-CoV-2 using age-stratified hospitalisation and serological data: a modelling study. *Lancet Public Health*. 2021;6(6):e408-e415. doi:10.1016/S2468-2667(21)00064-5

13. Salje H, Kiem CT, Lefrancq N, et al. Estimating the burden of SARS-CoV-2 in France. *Science*. 2020;369(6500):208-211. doi:10.1126/science.abc3517
14. Lapidus N, Paireau J, Levy-Bruhl D, et al. Do not neglect SARS-CoV-2 hospitalization and fatality risks in the middle-aged adult population. *Infect Dis Now*. Published online January 18, 2021. doi:10.1016/j.idnow.2020.12.007
15. Données relatives aux personnes vaccinées contre la Covid-19 (VAC-SI) - data.gouv.fr. Accessed July 1, 2021. <https://www.data.gouv.fr/en/datasets/donnees-relatives-aux-personnes-vaccinees-contre-la-covid-19-1/>
16. Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. *Lancet Lond Engl*. 2021;397(10287):1819-1829. doi:10.1016/S0140-6736(21)00947-8
17. Walsh EE, Frencck RW, Falsey AR, et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. *N Engl J Med*. 2020;383(25):2439-2450. doi:10.1056/NEJMoa2027906
18. Ramasamy MN, Minassian AM, Ewer KJ, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. *The Lancet*. 2020;396(10267):1979-1993. doi:10.1016/S0140-6736(20)32466-1
19. Ioannou GN, O'Hare AM, Berry K, et al. Trends over time in the risk of adverse outcomes among patients with SARS-CoV-2 infection. *Clin Infect Dis Off Publ Infect Dis Soc Am*. Published online May 11, 2021:ciab419. doi:10.1093/cid/ciab419
20. Müller L, Andrée M, Moskorz W, et al. Age-dependent immune response to the Biontech/Pfizer BNT162b2 COVID-19 vaccination. *Clin Infect Dis Off Publ Infect Dis Soc Am*. Published online April 27, 2021:ciab381. doi:10.1093/cid/ciab381
21. Les chiffres du R.E.I.N. - Agence de la biomédecine. Published July 1, 2021. Accessed July 2, 2021. <https://www.agence-biomedecine.fr/Les-chiffres-du-R-E-I-N>
22. Creput C, Fumeron C, Toledano D, Diaconita M, Izzedine H. COVID-19 in Patients Undergoing Hemodialysis: Prevalence and Asymptomatic Screening During a Period of High Community Prevalence in a Large Paris Center. *Kidney Med*. 2020;2(6):716-723.e1. doi:10.1016/j.xkme.2020.09.001
23. Tao K, Tzou PL, Nouhin J, et al. The biological and clinical significance of emerging SARS-CoV-2 variants. *Nat Rev Genet*. 2021;22(12):757-773. doi:10.1038/s41576-021-00408-x

Figure Legends

Figure 1: Nationwide vaccination coverage, and SARS-CoV-2 severe infections in patients needing maintenance dialysis and in the general population (adults aged at least 25 years).

Panel 1A: vaccine policies started in mid-January and first targeted patients with compromising health conditions such as dialysis patients among whom vaccination quickly reached a high coverage. National vaccination policies in the healthy population first targeted older individuals (nursing homes patients from December 27, patients over 75 years since January 18, patients over 65 years since early March and patients over 50 years since late March).

Panel 1B: incidence of severe infections in dialysis patients was approximately proportional to the dynamics in the general population during the two first epidemic waves. The relative incidence in dialysis patients dropped in early 2021, following the beginning of the vaccine policies.

Panel 1C: Model M_1 fitted on 1st wave data failed to capture an incidence drop in dialysis patient incidence from the beginning of the second wave. Model M_2 fitted on 1st and 2nd wave data failed to capture the early 2021 dynamics of incidence in dialysis patients, contrary to Model M_3 using vaccine exposures as additional predictors.

Tables

Table 1: Observed and predicted number of hospital admissions for SARS-CoV-2 infections in dialysis patients

| | 1 st wave | 2 nd wave | 3 rd wave | Total |
|----------------------------|----------------------|----------------------|----------------------|-------------------|
| Observed cases | 1233 | 1447 | 940 | 3620 |
| M ₁ predictions | 1265 (1156, 1397) | 2092 (1888, 2317) | 2021 (1874, 2194) | 5378 (5031, 5868) |
| M ₂ predictions | 1246 (1137, 1377) | 1475 (1371, 1577) | 1457 (1356, 1557) | 4179 (3957, 4382) |
| M ₃ predictions | 1258 (1190, 1333) | 1461 (1386, 1544) | 957 (938, 998) | 3685 (3552, 3816) |

Predicted number of severe infections (infection leading to hospital admissions) in dialysis patients with 95% credible intervals from models M₁ (fitted on 1st wave data, March 11 to June 30, 2020), M₂ (fitted on 1st and 2nd wave data, up to January 7, 2021) and M₃ (fitted on all 3 waves, up to April 29, 2021).




Table 2 : Coefficients from the Poisson regression models for incident hospitalizations for SARS-CoV-2 infection in dialysis patients

| Model M ₁ | |
|----------------------|-------------------|
| Variable | IRR (95% CI) |
| • Age class (years) | |
| - 25-35 | 4.04 (2.38, 6.51) |
| - 35-45 | 2.57 (1.85, 3.52) |
| - 45-55 | 1.37 (1.06, 1.76) |
| - 55-65 | 1 (reference) |
| - 65-75 | 0.85 (0.71, 1.02) |
| - 75-85 | 0.87 (0.73, 1.04) |
| - > 85 | 0.90 (0.73, 1.10) |

| Model M ₂ | |
|--------------------------|-------------------|
| Variable | IRR (95% CI) |
| • Age class (years) | |
| - 25-35 | 2.82 (1.90, 4.06) |
| - 35-45 | 2.17 (1.70, 2.75) |
| - 45-55 | 1.26 (1.04, 1.52) |
| - 55-65 | 1 (reference) |
| - 65-75 | 0.83 (0.74, 0.94) |
| - 75-85 | 0.74 (0.66, 0.85) |
| - > 85 | 0.82 (0.72, 0.95) |
| • Epidemic wave ≥ 2 | 0.70 (0.64, 0.76) |

| Model M ₃ | |
|---|-------------------|
| Variable | IRR (95% CI) |
| • Age class (years) | |
| - 25-35 | 2.92 (2.03, 4.09) |
| - 35-45 | 2.19 (1.74, 2.73) |
| - 45-55 | 1.32 (1.11, 1.56) |
| - 55-65 | 1 (reference) |
| - 65-75 | 0.88 (0.78, 0.98) |
| - 75-85 | 0.78 (0.70, 0.88) |
| - > 85 | 0.86 (0.76, 0.97) |
| • Epidemic wave ≥ 2 | 0.70 (0.64, 0.76) |
| • Vaccination coverage in the general population (per 10% increase) | 0.50 (0.40, 0.61) |
| • Vaccine exposure in dialysis patients | 0.37 (0.18, 0.71) |
| • Age–vaccine interaction in dialysis patients (years) | |
| - 25-35 | 0.00 (0.00, 4.66) |
| - 35-45 | 0.04 (0.00, 0.46) |
| - 45-55 | 0.55 (0.16, 1.72) |
| - 55-65 | reference |
| - 65-75 | 0.94 (0.43, 2.11) |
| - 75-85 | 1.74 (0.80, 3.86) |
| - > 85 | 2.30 (0.95, 5.56) |

Coefficients from the Poisson regression models are exponentiated and reported as incidence rate ratios (IRR) with their 95% credible intervals (CI).



Vaccination and COVID-19 Dynamics in Dialysis Patients

Supplemental Material

| | |
|---|---|
| Statistical model | 2 |
| Supplemental Tables | 4 |
| <i>Supplemental Table 1</i> : Description of the study populations | 4 |
| <i>Supplemental Table 2</i> : Crude number of hospitalizations, total at-risk population, cumulative incidence in dialysis and the general population and relative risk of hospitalization according to age classes and epidemic waves..... | 5 |
| <i>Supplemental Table 3</i> : Relative risks (95% credible intervals) of severe infection in dialysis patients, predicted from model M_3 , between April 2 and April 8, 2021 in Paris. | 6 |
| <i>Supplemental Table 4</i> : Coefficients from the Poisson regression (exponentiated and reported as incidence rate ratios with their 95% credible intervals): model M_3 (3- and 5-week lags between first dose and expected protection in the general population and in dialysis patients, respectively) and additional model with 3-week lags for all..... | 7 |
| References | 8 |

Statistical model

Infection dates

Infection dates in hemodialysis patients were actually those of diagnoses (either suspicious clinical symptom or chest scan / positive RT-PCR), which can be approximately considered as the dates of symptoms onset (1). Dates for severe infections in the general population were those of hospital admissions. In order to relate severe infections in dialysis patients (with known dates of symptoms onset) to those occurring simultaneously in the general population (with known dates of hospital admission), we subtracted the expected delay between symptoms onset and hospital admission. The chosen 11-day lag applied to hospitalization dates relies on previous estimates (2) and was already used in several modeling studies (3,4).

Modeling

We modeled weekly incidences SARS-CoV-2 severe infections (COVID-19 cases leading to hospital admissions) in dialysis patients from same-age incidences in the general population, with the use of hierarchical Bayesian Poisson regressions accounting for spatial autocorrelation.

All multivariable models were built from the following pattern:

$$\log\left(\frac{E(n_{a,d,w})}{e_{a,d,w}}\right) = \alpha + \beta \log(N_{a,d,w}) + \gamma_a a + \dots + \omega_d$$

With:

- $E(n_{a,d,w})$: expected number of cases in dialysis patients for age class a in department d on week w ($n_{a,d,w}$ following a Poisson distribution);
- $e_{a,d,w}$: exposed (at-risk) MHD patients for the same age / department / week;
- $N_{a,d,w}$: estimated incidence of severe infections in the general population for age class a in department d on week w ;
- β, γ_a : fixed effects to be estimated;
- ω_d : random effect accounting for spatial autocorrelation in department d ;
- ... : optional predictors with their associated fixed effects.

Spatial random effects were estimated with a covariance structure depending on neighborhood departments from a BYM model (5). Bayesian inference was performed using integrated nested Laplace approximation (6) and weakly informative priors.

Optional predictors were considered to fit the models:

- estimated incidence of severe infections in the general population for age class a in department d on week $w - 1$;
- epidemic wave on week w (dummy variables to identify epidemic waves 1 to 3);
- vaccination coverage (1st dose) in the general population in department d on week $w - 3$ (either in the age class a or globally);
- vaccination coverage (1st dose) in MHD patients in department d on week $w - 3$ (data stratified by age class was not available).

Other regression models (zero-inflated Poisson and negative binomial) were also considered to improve goodness-of-fit.

Predictors were selected to improve goodness-of-fit according to the Watanabe–Akaike information criterion (WAIC).

The following models were selected:

$$M_1: \log\left(\frac{E(n_{a,d,w})}{e_{a,d,w}}\right) = \alpha + \beta \log(N_{a,d,w}) + \beta' \log(N_{a,d,w-1}) + \gamma_a a + \omega_d$$

$$M_2: \log\left(\frac{E(n_{a,d,w})}{e_{a,d,w}}\right) = \alpha + \beta \log(N_{a,d,w}) + \beta' \log(N_{a,d,w-1}) + \gamma_a a + \delta k_w + \omega_d$$

With k_w taking values according to the epidemic wave ($k_w = 0$ if week w falls into the 1st wave and 1 otherwise) and δ the associated fixed effect to be estimated.

$$M_3: \log\left(\frac{E(n_{a,d,w})}{e_{a,d,w}}\right) = \alpha + \beta \log(N_{a,d,w}) + \beta' \log(N_{a,d,w-1}) + \gamma_a a + \delta k_w + \xi_0 u_{a,d,w-5} + \xi_a a \times u_{a,d,w-5} + \zeta v_{a,d,w-3} + \omega_d$$

With $u_{a,d,w}$ and $v_{a,d,w}$ the vaccination coverages in MHD patients and in the general population, respectively, for age class a on week w in department d , ξ_0 and ζ the associated fixed effects and ξ_a the fixed effect for interaction between a and $u_{a,d,w}$ to be estimated. The 3- and 5-week time lapses were set to account for a humoral response likely to impact incidence in the general population (7–10) and dialysis patients (11,12), respectively. All analyses were conducted with R statistical software version 4.0. Models were fitted with the INLA package (13).

Supplemental Tables**Supplemental Table 1 : Description of the study populations**

| | Dialysis patients (%) | General population (%) |
|-----------------------------|------------------------------|-------------------------------|
| Female sex | 38.5 | 52.8 |
| Age class (years) | | |
| • 25-35 | 2.2 | 16.3 |
| • 35-45 | 4.7 | 17.6 |
| • 45-55 | 8.7 | 18.6 |
| • 55-65 | 16.3 | 17.9 |
| • 65-75 | 28.5 | 16.0 |
| • 75-85 | 26.1 | 8.7 |
| • > 85 | 13.6 | 4.9 |
| Medical history | | |
| • Diabetes | 44.1 | |
| • Cancer | 10.2 | |
| • Respiratory disease | 15.8 | |
| • Coronary heart disease | 24.8 | |
| • Peripheral artery disease | 22.8 | |
| • Stroke | 12.1 | |
| • Obesity | 25.0 | |

Supplemental Table 2 : Crude number of hospitalizations, total at-risk population, cumulative incidence in dialysis and the general population and relative risk of hospitalization according to age classes and epidemic waves

| Age class | wave | Dialysis patients | | | General population | | | Relative risk (95% CI) |
|-----------|-----------------|-------------------|---------------------------|--------------------------|--------------------|---------------------------|--------------------------|------------------------|
| | | At-risk subjects | COVID-19 hospitalizations | Cumulative incidence (%) | At-risk subjects | COVID-19 hospitalizations | Cumulative incidence (%) | |
| 25-55 | 1 st | 7050 | 159 | 2.3% | 24,184,787 | 18,981 | 0.1% | 28.7 (24.6, 33.6) |
| | 2 nd | 7204 | 116 | 1.6% | 24,122,679 | 26,903 | 0.1% | 14.4 (12, 17.3) |
| | 3 rd | 6986 | 75 | 1.1% | 24,060,571 | 34,460 | 0.1% | 7.5 (6, 9.4) |
| 55-75 | 1 st | 19,304 | 512 | 2.7% | 15,328,488 | 32,833 | 0.2% | 12.4 (11.3, 13.5) |
| | 2 nd | 20,522 | 612 | 3% | 15,433,881 | 56,158 | 0.4% | 8.2 (7.6, 8.9) |
| | 3 rd | 20,144 | 395 | 2% | 15,539,273 | 60,795 | 0.4% | 5 (4.5, 5.5) |
| > 75 | 1 st | 16,974 | 562 | 3.3% | 6,194,203 | 47,424 | 0.8% | 4.3 (4, 4.7) |
| | 2 nd | 18,086 | 719 | 4% | 6,217,063 | 94,375 | 1.5% | 2.6 (2.4, 2.8) |
| | 3 rd | 18,036 | 470 | 2.6% | 6,239,923 | 74,961 | 1.2% | 2.2 (2, 2.4) |

Supplemental Table 3 : Relative risks (95% credible intervals) of severe infection in dialysis patients, predicted from model M₃, between April 2 and April 8, 2021 in Paris.

| Age class (years) | Vaccine exposure | |
|-------------------|-------------------|-------------------|
| | No | Yes |
| 25-35 | 0.74 (0.50, 1.09) | 0.00 (0.00, 12.4) |
| 35-45 | 1.01 (0.76, 1.35) | 0.02 (0.00, 0.21) |
| 45-55 | 0.98 (0.77, 1.26) | 0.20 (0.07, 0.54) |
| 55-65 | 1 (reference) | 0.37 (0.20, 0.69) |
| 65-75 | 0.89 (0.72, 1.11) | 0.31 (0.19, 0.52) |
| 75-85 | 0.70 (0.56, 0.87) | 0.45 (0.27, 0.73) |
| > 85 | 0.67 (0.53, 0.84) | 0.57 (0.30, 1.06) |

These relative risks of severe infection depend on the considered week and department, as their estimations use data on local vaccination coverage in dialysis patients and the general population. For this example, we chose the week and department with the highest number of cases during the third wave.

Supplemental Table 4 : Coefficients from the Poisson regression (exponentiated and reported as incidence rate ratios with their 95% credible intervals): model M3 (3- and 5-week lags between first dose and expected protection in the general population and in dialysis patients, respectively) and additional model with 3-week lags for all.

| Variable | Model M ₃ (3- and 5-week lags) | Sensitivity analysis (3-week-lags) |
|---|--|---------------------------------------|
| Age class (years) | | |
| - 25-35 | 2.92 (2.03, 4.09) | 2.85 (1.97, 4.02) |
| - 35-45 | 2.19 (1.74, 2.73) | 2.20 (1.75, 2.74) |
| - 45-55 | 1.32 (1.11, 1.56) | 1.35 (1.14, 1.60) |
| - 55-65 | 1 (reference) | 1 (reference) |
| - 65-75 | 0.88 (0.78, 0.98) | 0.87 (0.78, 0.98) |
| - 75-85 | 0.78 (0.70, 0.88) | 0.77 (0.69, 0.87) |
| - > 85 | 0.86 (0.76, 0.97) | 0.84 (0.74, 0.96) |
| Epidemic wave ≥ 2 | 0.70 (0.64, 0.76) | 0.69 (0.64, 0.75) |
| Vaccination coverage in the general population (per 10% increase) | 0.50 (0.40, 0.61) | 0.47 (0.38, 0.58) |
| Vaccine exposure in dialysis patients | 0.37 (0.18, 0.71) | 0.46 (0.26, 0.78) |
| Age class–vaccine interaction (years) | | |
| - 25-35 | 0.00 (0.00, 4.66) | 0.12 (0.00, 1.59) |
| - 35-45 | 0.04 (0.00, 0.46) | 0.13 (0.02, 1.56) |
| - 45-55 | 0.55 (0.16, 1.72) | 0.38 (0.13, 1.04) |
| - 55-65 | 1 (reference) | 1 (reference) |
| - 65-75 | 0.94 (0.43, 2.11) | 0.99 (0.53, 1.87) |
| - 75-85 | 1.74 (0.80, 3.86) | 1.80 (0.98, 3.37) |
| - > 85 | 2.30 (0.95, 5.56) | 2.48 (1.25, 4.92) |

References

1. Couchoud C, Bayer F, Ayav C, Béchade C, Brunet P, Chantrel F, et al. Low incidence of SARS-CoV-2, risk factors of mortality and the course of illness in the French national cohort of dialysis patients. *Kidney International*. 2020 Dec 1;98(6):1519–29.
2. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*. 2020 28;395(10229):1054–62.
3. Salje H, Kiem CT, Lefrancq N, Courtejoie N, Bosetti P, Paireau J, et al. Estimating the burden of SARS-CoV-2 in France. *Science*. 2020 Jul 10;369(6500):208–11.
4. Hozé N, Paireau J, Lapidus N, Kiem CT, Salje H, Severi G, et al. Monitoring the proportion of the population infected by SARS-CoV-2 using age-stratified hospitalisation and serological data: a modelling study. *The Lancet Public Health*. 2021 Jun 1;6(6):e408–15.
5. Besag J, York J, Mollié A. Bayesian image restoration, with two applications in spatial statistics. *Ann Inst Stat Math*. 1991 Mar 1;43(1):1–20.
6. Gomez-Rubio V. Bayesian inference with INLA. CRC Press; 2020. 308 p.
7. Bernal JL, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. *BMJ*. 2021 May 13;373:n1088.
8. Vasileiou E, Simpson CR, Shi T, Kerr S, Agrawal U, Akbari A, et al. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. *The Lancet*. 2021 May 1;397(10285):1646–57.
9. Thompson MG. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021. *MMWR Morb Mortal Wkly Rep [Internet]*. 2021 [cited 2021 Nov 9];70. Available from: <https://www.cdc.gov/mmwr/volumes/70/wr/mm7013e3.htm>
10. Wei J, Stoesser N, Matthews PC, Ayoubkhani D, Studley R, Bell I, et al. Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom. *Nat Microbiol*. 2021 Sep;6(9):1140–9.
11. Van Praet J, Reynders M, De Bacquer D, Viaene L, Schoutteten M, Caluwé R, et al. Predictors and Dynamics of the Humoral and Cellular Immune Response to SARS-CoV-2 mRNA Vaccines in Hemodialysis Patients: A Multicenter Observational Study. *J Am Soc Nephrol*. 2021 Sep 29;ASN.2021070908.
12. Stumpf J, Siepmann T, Lindner T, Karger C, Schwöbel J, Anders L, et al. Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine. *The Lancet Regional Health - Europe*. 2021 Oct 1;9:100178.
13. Rue H, Martino S, Chopin N. Approximate Bayesian inference for latent Gaussian models by using integrated nested Laplace approximations. *Journal of the Royal Statistical Society: Series B (Statistical Methodology)*. 2009;71(2):319–92.